Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease

Is ticagrelor noninferior to prasugrel after percutaneous coronary intervention in patients with diabetes and multivessel disease?In this randomized clinical trial, among 1800 participants with diabetes and multivessel disease randomized to ticagrelor or prasugrel plus aspirin, the 1-year primary composite end point (death, myocardial infarction, stroke, or major bleeding) did not differ between the treatments. The risk difference failed to meet the prespecified 5% noninferiority margin.Ticagrelor did not demonstrate noninferiority to prasugrel in this high-risk population with diabetes and multivessel disease.

Corresponding Author: Sripal Bangalore, MD, MHA, NYU Langone Health, NYU Grossman School of Medicine, New York, NY 10016 (sripalbangalore@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.